EBITDA: Income before interest, taxes, depreciation and amortization.
Aspire Biopharma Holdings, Inc. (ASBP) had EBITDA of $-0.06M for the most recently reported fiscal quarter, ending 2026-03-31.
| Income Statement Financials | |
$0.03M |
|
$-3.22M |
|
$0.02M |
|
$0.01M |
|
$1.67M |
|
$-1.65M |
|
$-1.58M |
|
$-3.22M |
|
$-3.22M |
|
$-3.22M |
|
$-3.22M |
|
$-3.22M |
|
$-3.22M |
|
$-1.65M |
|
|
EBITDA |
$-0.06M |
0.16M |
|
0.16M |
|
$-20.57 |
|
$-20.57 |
|
| Balance Sheet Financials | |
$7.12M |
|
-- |
|
-- |
|
$7.12M |
|
$3.15M |
|
-- |
|
$0.10M |
|
$3.25M |
|
$3.87M |
|
$3.87M |
|
$3.87M |
|
0.17M |
|
| Cash Flow Statement Financials | |
$-3.04M |
|
-- |
|
$7.89M |
|
$1.00M |
|
$5.86M |
|
$4.85M |
|
$0.01M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
2.26 |
|
-- |
|
-- |
|
-- |
|
0.39 |
|
20.28% |
|
-5805.98% |
|
-5805.98% |
|
-- |
|
-11367.02% |
|
-11367.02% |
|
$-3.04M |
|
-- |
|
-- |
|
-- |
|
0.00 |
|
0.06 |
|
-- |
|
-- |
|
-83.31% |
|
-83.31% |
|
-45.28% |
|
-83.31% |
|
$23.10 |
|
$-19.39 |
|
$-19.39 |
|